The Pharma Letter7h
Semaglutide 7.2mg achieved 20.7% weight loss in STEP UP obesity trial
Danish diabetes and obesity giant Novo Nordisk today announced headline results from STEP UP, a Phase IIIb trial in the ...
Monthly Prescribing Reference3h
STEP UP Trial: Significant Weight Loss Observed With Higher Dose Semaglutide
The phase 3 STEP UP trial enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2 and without diabetes.
Novo Nordisk’s Semaglutide 7.2mg s.c. achieved 21% weight loss in STEP UP trial
Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
muhc.ca2d
Semaglutide - known as Ozempic - can be beneficial to people with type 1 diabetes
A first randomized clinical trial shows that semaglutide use in type 1 diabetes is associated with improved glucose management, weight loss and lower insulin requirements. Semaglutide (known by its ...
Metro Times7d
What Is the Ideal Semaglutide Dose for Weight Loss?
The best semaglutide dose for weight loss varies according to your starting weight, risks, and stage of treatment. Read to ...
Novo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...
France29d
Semaglutide: Peptides’ Potential in Scientific Domains
Among these, Semaglutide and Tirzepatide are particularly intriguing because of their theoretical roles as peptide-based research agents. Both peptides are engineered to mimic endogenous molecules ...